PTO/SB/08a (08-03)
Approved for use through 07/31/2006. OMB 0851-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for	form 1449A/PTO			Cor	mplete if Known	
30030000	101111 1440/41 10			Application Number		
INFOR	RMATION E	nsci d	SURF	Filing Date		•
	EMENT BY			First Named Inventor	Hsing-Wen	Sung.
SIAII		AFFL	IOAN	Art Unit	9	- 5
	(Use as many sheets	as necessar	v)	Examiner Name		
eet	1	of	5	Attorney Docket Number	5 &T- 120	5

			U. S. PATENT	DOCUMENTS	
Examiner Initials*	Cite No. <sup>1</sup>	Document Number  Number-Kind Code <sup>2 (f known)</sup>	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
Sul		US-4,806,595	2-21-89	Noishiki etal.	all
BU -		US- 5,0 37, 664	8-6-91	Krogoku atal.	au)
W-		US-5,0 85,629	2-4-92	Goldberg et al.	all
and		US-5,270,446	12-14-93	Kyogoku etal	all
an		US- 5,322,935	6-21-94	Smith	all
are		US- 5,464,450	=11-7-95	Buscemi et al.	all
ar		US- 5,516,781	5-14-96	Morris otal.	all
ark		US- 5,780,052	7-14-98	Khaw et al.	911
arl		US- 5, 929,038	7-27-99	chang	all
ay		US. 6,103,255	8-15-00	Levene et al.	<u> 911                                  </u>
au		US- 6,162, 826	12-19-00	Moon etal.	all
an		6,200, 335	3-13-01	IgaKi	all
anh		03 6, 200, 931	3-27-01	Cook stal	all
ann		US- 6,262,083	7-17-01	Moon otal.	<u>all</u>
an	<u> </u>	US- 6,264,992	7-24-01	Voytik-Harbin etal.	<u> </u>
arl	•	6395,300	5-18-02	Straub at al.	au
only		1 - 6,4 2 3, 68 2	7-23-02	Ballinger et al.	all
anto		US- 6,436,703	8-20-02	Tana stal.	col. 1-6

	FOREIGN PATENT DOCUMENTS												
Examiner Initials*	Cite No.1	Foreign Patent Document  Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (# known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	T⁴							
		Country Code" Number   Nind Code" (# Known)			or Relevant Figures Appear								
			)	**************************************	***************************************								
			· · · · · · · · · · · · · · · · · · ·	*************************************	***************************************								
			) > + + + + + + + + + + + + + + + + + +	<b>,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,</b>	***************************************	<u> </u>							

\*EXAMNER: Intelligence considered, whether owner chation is in conformance with MPEP 609. Draw line through citation in not in conformance and not considered, include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language

Date Considered

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

a deside	- the Do	perwork Reduction Act of 1995, no		eans am maulm	d to men	l'.S.U	Patent and Tradem	ark Office; U.	S. DEPARTMENT OF COMME	RCE
			J Del	SOIIS ATT TROUTER	TO LEAST		Co	nplete if	Known	
Sut	ostitule f	or form 1449A/PTO				Applicatio	n Number		<u> </u>	$\neg$
18	IEO	RMATION DISCI		SUPE	h	Filing Date		<del></del>		
		EMENT BY APP			. Ի	First Nam	ed Inventor	Heina	Wen Sung	$\dashv$
3	IAI	ENENI DI AFF	L	CANI	T	Art Unit		1131119 =	WEN BRIDE	
•		Ales en manu chaste no massa		d	-  -	Examiner	Name			
Sheet		(Use as many sheets as neces	of	5	<del></del>	Attorney C	Oocket Number	54	7-125	$\neg$
311001										
			<u>.</u>	U.S. PAT					0	
Examiner Initials*	Cite No.¹	Document Number	-	Publication D MM-DD-YY			me of Patentee or ant of Cited Docum		Pages, Columns, Lines, Where Relevant Passages or Relevant	
		Number-Kind Code <sup>2 (# known)</sup>	4-			ļ			Figures Appear	
arh	<u> </u>	US-6,451,764	4	9-17-02		Lee	et al.		1.1-6	
an		US- 6,475,784	_	11-5-02		Pape	off		1.1-14	
ark	<u> </u>	US- 6,476,211	_ _	11-5-02			otal.		1. 1-8	
any	<b></b>	US- 6,485,920	_	11-26-03	L	Ball	inger otal		1.69-70	
are		US- 6,544,544	_	4-8-03		Hun	teretal.	c	ol. 1-86	
ann		US- 6,545,042	_	4-8-03			et al.		Ш	
ary-		6,624,138	$\perp$	9-23-03		وستك_			<u> </u>	
au		US- 6,608,040	_ _	8-19-03		Lin	etal.		۱(	
an	ļ <u>.</u>	US- 6,632,242	$\perp$	10-14-0	3	Igak	≤i	a	.(1	
		US	┸			<u> </u>			•	
		US-	$\perp$			ļ				
		US-	_				<del></del>			
		US-	_							
	ļ!	US-	_ _							
		US-	$\perp$							
		US-	$\perp$			<b> </b>				
		US-	$\perp$			ļ			······································	
		US-					·····			
			F	OREIGN P	ATEN	T DOCL	MENTS			
Examiner	Cite	Foreign Patent Doc	uma		Publica	tion Date	Name of Pat	entee or	Pages Columns Lines	
Initials*	No.'	Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>6</sup> (		***************************************	MM-DD-		Applicant of Cite			ן זי
									O. T. G.	М
		**************************************				4.0144.00.00	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	*****************	·*************************************	$\vdash \vdash \vdash$
	ļ	***************************************	******			***************************************	**********************	***************	1000 0071 (000 1000) 1000 000 (100 000 100 000 100 100 100 1	$\vdash\vdash\vdash$
		***************************************	******			****	924 <del>3</del> 4 34 5 6 6 6 6 6 7 7 9 7 7 7 7 7 7 7 7 7 7 7 7	***************	1 mai 1 mai 1 mai anta de la colonia de la colonia de 1 mai 1 m	Н
	<u> </u>						<b></b>	*******		LJ

Signature \*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of the conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language

Date Considered

Examiner

Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Petent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Subs	itute for form 1449B/F	РТО			Complete If Known			
					Application Number			
IN	FORMATI	ON DI	SCLO	SURE	Filing Date			
S	ATEMEN	T BY	<b>APPLI</b>	CANT	First Named Inventor	Hsing-Wen Sung		
					Art Unit			
	(Use as man	y sheets as	песеззегу	)	Examiner Name			
She	et	3	of	5	Attorney Docket Number	S&T-125		

	NON PATENT LITERATURE DOCUMENTS								
Examiner Initials*	Cite No.¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²						
an	1.	RADER DJ, "High-density lipoproteins as an emerging therapeutic target for atherosclerosis", JAMA 2003; 290(11): 2322-2324	***********						
arl	2.	NISSEN SE etal., Effect of Recombinant ApoA-1 Milano on coronary atheroscleross in patients with acute coronary Symdroms", JAMA 2003; 290(17): 2292-2300	********						
are	₹.	NAGHAVIM et al, "From vulnerable plaque to vulnerable patient - part I"  Circulation 2003;108:1664-1672							
anh	4	NAGHAVI M et al., "From vulnerable plague to Vulnerable patient-part I"  Circulation 2003; 108: 1772-1778							
ark	5	RODRIGUEZ AE et al.) "Dral rapamy cin in the treatment of diffuse  Proliferative in-stent restenosis in a patient with Small reference vessel"  I Invasiv Cardio 2003; 15(9): 515-518							
are	6	SUNG HW et al., "Feasibility study of a natural crosslinking reagent for biological tissue fixation" J Biomed Mater Res 1998; 42:560-567							
ar	7	HUANG LL et al., "Biocompatibility study of a biological tissue fixed with a naturally occurring crosslinking reagent" J Biomed Meter Res 1998; 42: 568-576	***************************************						
are	ક	SUNG HW et al.," In vitro evaluation of cytotoxicity of a naturally occurring cross-linking reagent for biological Hissue fixation", J Biomater Sci Polymer Edn 1999; 10(1): 63-78							
au	9	SUNG HW etal., "A naturally occurring crosslinking reagont for biological tissue fixation" in New Biomedical Materials, edited by Haris PI and Chapman D. pages 182-191 (1998). published by IOS Press							
BUL	10	SUNG HW et al., "Crosslinking characteristics and mechanical properties of a bovine pericardium fixed with a naturally occurring crosslinking agent"  I biomed Mater Res 1999: 47: 116-126							

Examiner Signature Con	e usidered

<sup>&#</sup>x27;EXAMINER: Injuit If reference considered, whether not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, which next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

	Substitute for	form 1449B/PTO				Complete if Known
	•				Application Number	
	INFO	RMATION D	ISCLO	SURE	Filing Date	
	STAT	EMENT BY	<b>APPLI</b>	CANT	First Named Inventor	Hsing-Wen Sung
					Art Unit	-
		(Use as many sheets a	s necessary	)	Examiner Name	
T	Sheet	4	of	5	Attorney Docket Number	S&T-125

Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.  SUNG HW etal.) "Mechanical properties of a porcine aortic valve fixed with a naturally occurring crosslinking agent Biomaterials 1999;  20: 1759-1772  SUNG HW etal., "In vitro surface characterization of a bibliogical patch
fixed with a naturally occurring crosslinking agent Biomaterials 1999;  20: 1759-1772  COUG HUD stale. "In vitro surface characterization of a biological patch
SUNG HW stal, " In vitro surface characterization of a biological parch
fixed with a naturally occurring crosslinking agent Biomaterials 2000
TSAI CC etal., "In vitro evaluation of the genetoxicity of a naturally occurring crosslinking agent (genipin) for biologic tissue fixation" J Biomed
Mater Res 2000; 52: 58-65  SUNG HW et al., "Fination of biological tissues with a naturally occurring crosslinking agent: Fination rate and effects of pH, temperature, and initial fixative concentration" J Bigmed Mater Res 2000; 52: 77-87
15 SUNG HW etal., Extraction of a naturally occurring crosslinking agent (Genipin) from Gardenia fruits and its applications in biological tissue fixation"  Biomaterials and Drug Dolivery toward New Mellenium, edited by Park KD  etal., pages 623-692 (2000), published by Han Rin Won Publishing Co.
16. TSAI CC et al., "Effects of heparin immobilization on the surface characteristics of a biological tissue fixed with a naturally occurring crosslinking agent " Biomaterials 2001; 22: 523-533
17 SUNG HW etal., "Stability of a biological tissue fixed with a naturally occurring crosslinking agent (genipin)" J Bromed Mater Res 2001; 55: 538-546
With a bovine jugular vein grate fixed with a naturally occurring crosslinking agent (genipin) in a canine model. I Thorac Cardiovas Surg.

Examiner Signature Signature Considered 11/06/2007

<sup>\*</sup>EXAMINER: Initial Meference considered, whether or so citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Complete If Known

Approved for use through 06/30/2006. OMB 0651-0031

U.S. Petent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Application Number

Substitute for form 1449B/PTO

Examiner

Signature

INFO	KMA	HON L	DISCLO	SURE	Filing Date	<u>'</u>				
STAT	EME	NT BY	'APPLI	CANT	First Named Inventor	Hsing-Wen Sung				
					Art Unit	12.9				
•	(Use as	many sheets	as necessary)		Examiner Name					
Sheet		5	of	5	Attorney Docket Number	S&T- 125				
				NON PATE	NT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No.1	magazir	ne, journal, se	rial, symposiur	n, catalog, etc.), date, page(s and/or country where publis	cle (when appropriate), title of the item (book, s), volume-issue number(s), publisher, city shed.	T²			
an	19					nd degradability of a novel ials 2002; 23:181-191				
	20	cHANG pericardi Biomate	Y etal., ia fixed rials 20	"In vivo e with a r oz; z; ;	evaluation of collula naturally occurring c 2447-2457	er and acellular bovine crosslinking agent (genipin)				
are	2/	LIANG camer - J Biomer	pericardia fixed with a naturally occurring crosslinking agent (genipin)  Biomaterials 2002; 23: 2447-2457  LIANG HC etal., "Genipin-crosslinked gelatin microspheres as a dr  carrier for intramuscular administration: in vitro and in vivo studies"  J Biomed Mater Res 2003; 65A: 271-282							
			,							
************************	***************************************	• • • • • • • • • • • • • • • • • • •	***************************************	0.9 010 pr 100 to 0 p 2 4 4 0 0 2 4 4 2 p 4 2	***************************************		,			
		***************************************	***************************************		1991 - 1991 - 1991 - 1991 - 1991 - 1991 - 1991 - 1991 - 1991 - 1991 - 1991 - 1991 - 1991 - 1991 - 1991 - 1991		***********			
			***************************************	12 <b>200</b> 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	***************************************		************			
				***************************************						
				90 <b>9</b> 94 494 494 994 494 <del>994 99</del> 5 995 995 995 995 995 995 995 995 99		·	************			
	/						_			

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Date

Considered

considered. Include\_zopy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.